EVOK vs ANIP

For growth investors, Evoke Pharma, Inc.

(EVOK) is the stronger pick with 97. 8% revenue growth year-over-year, versus 43. 8% for ANI Pharmaceuticals, Inc. (ANIP). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 25. 3x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +117. 4%, compared to -95. 2% for Evoke Pharma, Inc. (EVOK). Over 10 years, the gap is even starker: ANIP returned +80. 2% versus EVOK's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Evoke Pharma, Inc.

(EVOK) is the lower-risk stock at -0. 17β versus ANI Pharmaceuticals, Inc. 's 0. 56β — meaning ANIP is approximately -436% more volatile than EVOK relative to the S&P 500. On balance sheet safety, ANI Pharmaceuticals, Inc. (ANIP) carries a lower debt/equity ratio of 60% versus 73% for Evoke Pharma, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evoke Pharma, Inc.

(EVOK) is pulling ahead at 97. 8% versus 43. 8% for ANI Pharmaceuticals, Inc. (ANIP). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to 90. 0% for Evoke Pharma, Inc.. Over a 3-year CAGR, EVOK leads at 85. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ANI Pharmaceuticals, Inc.

(ANIP) is the more profitable company, earning 8. 9% net margin versus -52. 2% for Evoke Pharma, Inc. — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIP leads at 12. 6% versus -50. 8% for EVOK. At the gross margin level — before operating expenses — EVOK leads at 96. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Evoke Pharma, Inc.

(EVOK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 17)). Both have compounded well over 10 years (EVOK: -98. 5%, ANIP: +80. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.